US5688501A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Antibacterial therapy with bacteriophage genotypically modified to delay inactivation by the host defense system
Assignee: Exponential Biotherapies Inc
•
Filing: 1996-01-29
•
Granted: 1997-11-18
•
Expires: 2016-01-29
Abstract
Abstract The present invention is directed to bacteriophage therapy, using methods that enable the bacteriophage to delay inactivation by any and all parts of the host defense system (HDS) against foreign objects that would tend to reduce the numbers of bacteriophage and/or the efficiency of those phage at killing the host bacteria in an infection. Disclosed is a method of producing bacteriophage modified for anti-HDS purposes, one method being selection by serial passaging, and the other method being genetic engineering of a bacteriophage, so that the modified bacteriophage will remain active in the body for longer periods of time than the wild-type phage.
Inventors
- 👤 Carl R. Merril
- 👤 Richard M. Carlton
- 👤 Sankar L. Adhya
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-05 19:26
CPC Classifications
C; C12; C12N; C12N7/00; A; A61; A61K; A61K35/00; A61K35/66; A61K35/76; A61P; A61P31/00; A61P31/04; C07; C07K; C07K14/00; C07K14/005; C07K14/435; C07K14/46; C07K14/47; C07K14/4701; C07K14/472; C07K2319/00; C12N2795/00; C12N2795/00011; C12N2795/10011; C12N2795/10311; C12N2795/10322; C12N2795/10332; C12N2795/10361; C12N2795/10364; Y; Y02; Y02A; Y02A50/00; Y02A50/30
Claims Analysis
Total Claims: 19
Claim 1
Independent Claim
109 words
A method for treating an infectious disease caused by bacteria in an animal comprising: administering to an animal in need of such treatment lytic or non-lytic bacteriophages that are specific for said bacteria in a dosage effective to substantially eliminate the bacteria, wherein said bacteriophages are obtained by serial passage through an animal's circulatory system of mutagenized or non-mutagenized bacteriophages and are selected to have at least a 15% longer half-life in the animal's circulatory system than corresponding wild-type bacteriophages, wherein said at-least 15% longer half-life is genetically inheritable and wherein said bacteriophages having at least 15% longer half-life contact said bacteria during the course of the infectious disease.
Claim 2
Independent Claim
109 words
A method for treating an infectious disease caused by bacteria in an animal comprising: administering to an animal in need of such treatment lytic or non-lytic bacteriophages that are specific for said bacteria in a dosage effective to substantially eliminate the bacteria, wherein said bacteriophages are obtained by serial passage through an animal's circulatory system of mutagenized or non-mutagenized bacteriophages and are selected to have at least a 15% longer half-life in the animal's circulatory system than corresponding wild-type bacteriophages, wherein said at-least 15% longer half-life is genetically inheritable and wherein said bacteriophages having at least 15% longer half-life contact said bacteria during the course of the infectious disease.
Claim 3
Dependent Claim
13 words
The method according to claim 1, wherein said bacteria are drug resistant bacteria.
Claim 4
Dependent Claim
13 words
The method according to claim 1, wherein said animal is not a mammal.
Claim 5
Dependent Claim
12 words
The method according to claim 1, wherein said animal is a mammal.
Claim 6
Dependent Claim
20 words
The method according to claim 1, wherein the bacteriophages are administered by way of an aerosol to an animal's lungs.
Claim 7
Dependent Claim
23 words
The method according to claim 1, wherein the bacteriophages are administered at a dosage of about 10 6 to about 10 13 pfu/kg/day.
Claim 8
Dependent Claim
19 words
The method according to claim 6, wherein the bacteriophages are administered at a dosage of about 10 12 pfu/kg/day.
Claim 9
Dependent Claim
12 words
The method according to claim 1, wherein said infectious disease is systemic.
Claim 10
Dependent Claim
44 words
The method according to claim 1, wherein the bacteria belong to a genus selected from the group consisting of Mycobacteria, Staphylococci, Vibrio, Enterobacter, Enterococcus, Escherichia, Haemophilus, Neisseria, Pseudomonas, Shigella, Serratia, Salmonella, Streptococcus, Klebsiella and Yersinia, and wherein the bacteriophages can effectively lyse the bacteria.
Claim 11
Dependent Claim
29 words
The method according to claim 9, wherein the bacteria belong to the genus Mycobacteria and are selected from the group consisting of Mycobacterium tuberculosis, Mycobacterium avium-intracellulare and Mycobacterium bovis.
Claim 12
Dependent Claim
23 words
The method according to claim 1, wherein said bacteriophages having at least 15% longer half-life contact said bacteria via the animal's circulatory system.
Claim 13
Dependent Claim
49 words
Isolated and purified bacteriophages that have been obtained by serial passage of mutagenized or non-mutagenized bacteriophages through an animal's circulatory system and selected to have at least a 15% longer half-life in said animal's circulatory system than corresponding wild-type bacteriophages, wherein said at-least 15% longer half-life is genetically inheritable.
Claim 14
Dependent Claim
49 words
Isolated and purified bacteriophages that have been obtained by serial passage of mutagenized or non-mutagenized bacteriophages through an animal's circulatory system and selected to have at least a 15% longer half-life in said animal's circulatory system than corresponding wild-type bacteriophages, wherein said at-least 15% longer half-life is genetically inheritable.
Claim 15
Dependent Claim
36 words
The bacteriophages of claim 12, wherein said bacteriophages are specific for a bacterial genus selected from the group consisting of Mycobacteria, Staphylococci, Vibrio, Enterobacter, Enterococcus, Escherichia, Haemophilus, Neisseria, Pseudomonas, Shigella, Serratia, Salmonella, Streptococcus, Klebsiella and Yersinia.
Claim 16
Dependent Claim
60 words
A pharmaceutical composition comprising isolated and purified bacteriophages that have been obtained by serial passage of mutagenized or non-mutagenized bacteriophages through an animal's circulatory system and selected to have at least a 15% longer half-life in said animal's circulatory system than corresponding wild-type bacteriophages, wherein said at-least 15% longer half-life is genetically inheritable, in combination with a pharmaceutically acceptable carrier.
Claim 17
Dependent Claim
60 words
A pharmaceutical composition comprising isolated and purified bacteriophages that have been obtained by serial passage of mutagenized or non-mutagenized bacteriophages through an animal's circulatory system and selected to have at least a 15% longer half-life in said animal's circulatory system than corresponding wild-type bacteriophages, wherein said at-least 15% longer half-life is genetically inheritable, in combination with a pharmaceutically acceptable carrier.
Claim 18
Dependent Claim
20 words
The pharmaceutical composition according to claim 14, wherein said composition is an aerosol formulation for administration to an animal's lungs.
Claim 19
Dependent Claim
14 words
The pharmaceutical composition according to claim 14, wherein said bacteriophage is in lyophilized form.
References Cited (Backward Citations)
US4332897A
Cited
US4375734A
Cited
US4865979A
Cited
US4797363A
Cited
US4946778A
Cited
US5132221A
Cited
US4957686A
Cited
US5344822A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2000-11-17 | 2001-05-19 | 2001-11-18 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2004-11-17 | 2005-05-19 | 2005-11-18 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2008-11-17 | 2009-05-19 | 2009-11-18 | $7700.00 | Window Closed / Lapsed |